Literature DB >> 27432671

Extra-axial brain tumors.

Otto Rapalino1, James G Smirniotopoulos2.   

Abstract

Extra-axial brain tumors are the most common adult intracranial neoplasms and encompass a broad spectrum of pathologic subtypes. Meningiomas are the most common extra-axial brain tumor (approximately one-third of all intracranial neoplasms) and typically present as slowly growing dural-based masses. Benign meningiomas are very common, and may occasionally be difficult to differentiate from more aggressive subtypes (i.e., atypical or malignant varieties) or other dural-based masses with more aggressive biologic behavior (e.g., hemangiopericytoma or dural-based metastases). Many neoplasms that typically affect the brain parenchyma (intra-axial), such as gliomas, may also present with primary or secondary extra-axial involvement. This chapter provides a general and concise overview of the common types of extra-axial tumors and their typical imaging features.
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  dural-based mass; extra-axial brain tumor; meningiomas; metastasis; neurofibroma; peripheral nerve sheath tumors; schwannoma; solitary fibrous tumor

Mesh:

Year:  2016        PMID: 27432671     DOI: 10.1016/B978-0-444-53485-9.00015-5

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  3 in total

Review 1.  [Extra-axial tumors of the central nervous system].

Authors:  R Mühl-Benninghaus
Journal:  Radiologe       Date:  2017-09       Impact factor: 0.635

2.  Pathological Spectrum of Dura-Based Nonmeningothelial Lesions: 5 Years' Experience from a Tertiary Care Centre.

Authors:  Shilpa Rao; Chitra Chandran; Subhas Konar; Anita Mahadevan; Vani Santosh; B N Nandeesh
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-22

3.  Possible Abscopal Effect Observed in Frontal Meningioma After Localized IMRT on Posterior Meningioma Resection Cavity Without Adjuvant Immunotherapy.

Authors:  Danielle Golub; Kevin Kwan; Jonathan P S Knisely; Michael Schulder
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.